CASE REPORT

Innovative Treatment for Inferior Vena Cava Thrombosis without Use of Thrombolytics
Maxwell Isaac¹, Fnu Marium²

¹William Carey College of Osteopathic Medicine, Hattiesburg, MS
²University of Missouri, Columbia, MO

Corresponding author: Maxwell Isaac. 42 Meadowrue Lane, East Northport, NY 11731 (misaac347539@student.wmcarey.edu)

Received: September 16, 2019  Accepted: March 6, 2020  Published: March 31, 2020

Am J Hosp Med 2020 Jan;4(1):2020.002  https://doi.org/10.24150/ajhm/2020.002

Abstract: Limb ischemia and pulmonary embolism are devastating complications of deep vein thrombosis. Catheter directed thrombolysis (CDT) and pharmacomechanical thrombolysis are effective treatments, however thrombolytics in these procedures increase the risk of bleeding. Moreover, they lengthen hospital stays and have many contraindications. The Inari ClotTriever is an innovative device for percutaneous mechanical thrombectomy. We present a case of an ileofemoral DVT with extension to the inferior vena cava removed without thrombolytics.

Keywords: percutaneous mechanical thrombectomy, thrombosis, inferior vena cava, thrombolytic, ClotTriever

INTRODUCTION

As many as 900,000 Americans are affected each year by DVT.¹ Yet, only 4% of patients with lower extremity thrombosis have extension to the inferior vena cava.² Risk factors for clot formation are classically explained by Virchow’s triad. It states that endothelial injury, venous stasis, and hypercoagulability promote thrombus formation.

Although anticoagulation is the cornerstone of treatment, invasive therapies are used for ileofemoral DVT with severe swelling.³ CDT is a minimally invasive procedure that delivers a low dose of thrombolytics.⁴ It provides an alternative to the larger doses given in systemic treatment. Thrombolytic doses were further reduced by the introduction of pharmacomechanical thrombolysis. Thrombolytics are delivered into the clot in combination with maceration or aspiration.⁵ The emergence of percutaneous mechanical thrombectomy provides a treatment option without thrombolytic use. The Inari ClotTriever is designed to remove clots from large veins using small access sites.

CASE PRESENTATION

A 34 year old female patient presented with worsening right groin and leg pain for two days. Her past medical history includes common variable immune deficiency, chronic colitis, and bilateral simple ovarian cysts. She described a constant stabbing pain extending towards her calf. There was no recent trauma to the area. Additionally, she reported thigh swelling, night sweats, and a temperature of 100.1 F (37.83 C) beginning two days before presentation. She denied
chills, chest pain, dyspnea, oliguria, or IV drug use. There is no personal or family history of clots. Surgical history includes a hysterectomy two years prior, sinus surgery, and one cesarean section. She takes subcutaneous immune globulin weekly to supplement her deficiency.

Physical exam revealed a warm, tender right leg with soft compartments. There was moderate swelling and erythema without phlegmasia. Hip and knee flexion were reduced secondary to pain and pulses were present. Abdominal exam showed pain in the right lower quadrant. No rebound tenderness was appreciated and the patient had normoactive bowel sounds. The remainder of the exam was unremarkable. Abdominal and pelvic CT scans revealed a thrombus in the IVC (Image 1). Fat stranding was noted from the IVC confluence spreading continuously down into the right groin and partially imaged femoral vessels. Ultrasound illustrated a thrombus from the common femoral vein to the saphenofemoral junction (Image 2). The popliteal and calf veins were patent. During this admission, hypercoagublility testing uncovered a heterozygous prothrombin 20210G>A mutation.

![Image 1](Image 1. CT scan of abdomen and pelvis demonstrating IVC extension of ileofemoral thrombus (dashed oval) through the right common iliac vein.)
Heparin therapy was started initially and an IVC filter was placed. On hospital day three a percutaneous manual thrombectomy was performed using the Inari ClotTriever. Venous access through the right popliteal vein was achieved using ultrasound. The ClotTriever catheter was advanced into the distal femoral vein under fluoroscopic guidance. To prevent shearing of the collection bag, a sheath was inserted from the right internal jugular vein just past the IVC filter. Venography showed extensive thrombosis from the IVC to the distal femoral vein (Image 3). The Inari ClotTriever was advanced from the distal femoral vein into the IVC. The collection bag was then deployed. Mechanical thrombectomy was performed from the IVC through the femoral vein yielding a significant thrombus (Image 4). Four total passes were performed and completion venography illustrated resolution of the clot (Image 5). The patient reported mild soreness and swelling immediately after the procedure. No complications occurred from the procedure during the hospital stay. She was discharged on the second postoperative day with apixaban.
**Image 4.** Specimens removed from patient using percutaneous mechanical thrombectomy. 60cc syringe and ruler included for reference.

**Image 5.** Venography following completion of percutaneous mechanical thrombectomy. In-line flow is visualized from distal superficial femoral vein through the IVC.
DISCUSSION

Early treatment of deep vein thrombosis helps prevent complications including limb ischemia and pulmonary embolism. Popular techniques include catheter directed thrombolysis (CDT) and pharmacomechanical thrombolysis. These procedures use localized thrombolytics to dissolve clots. However, thrombolytics have serious adverse effects including an increased risk for bleeding.\(^5\), \(^6\), \(^7\) The ATTRACT trial concluded that compared to anticoagulation alone, pharmacomechanical thrombolysis carries an increased risk for bleeding without a difference in quality of life.\(^5\) In addition, patients receiving thrombolytics have longer hospital stays.\(^7\) One possible explanation is procedure time. CDT often requires multiple treatment sessions and infusion times up to 72 hours.\(^2\) An alternative explanation is the need to monitor for possible bleeding. The Society of Interventional Radiology recommends that patient’s hematocrit, platelet count, and PTT be checked every twelve hours.\(^8\) They also encourage frequent examinations for impending signs of bleeds, including pericatheter oozing and epistaxis.

Predictably, thrombolytic use has many contraindications.\(^8\) These criteria limit treatment options for many patients. A review of vascular referrals at one tertiary center found that only 37% of patients diagnosed with acute DVT had no absolute contraindications for CDT.\(^9\) Percutaneous mechanical thrombectomy provides an option for patients who do not qualify for thrombolytic therapy. It is a relatively new approach to clot removal without thrombolytics. In our case, the Inari ClotTriever successfully restored in line flow through the iliofemoral veins.

Large randomized controlled trials are required to contrast percutaneous mechanical thrombectomy against thrombolytic treatments. Early research shows that compared to CDT, percutaneous mechanical thrombectomy has decreased ICU stays, bleeding complications, and total hospital costs.\(^10\) Additionally, limited data exists documenting adverse effects and long-term outcomes of ClotTriever therapy. The CLOUT registry is an ongoing prospective cohort study that will demonstrate all-cause mortality, major bleeding, and treatment success.

Notes

**Potential conflicts of interest:** Authors declare no conflicts of interest.

**References**

1. Prevention ClidCa. Venous Thromboembolism (Blood Clots) [Internet]. www.cdc.gov2019 [cited 2019 9/5/2019]. Data and Statistics from the CDC]. Available from: https://www.cdc.gov/nchbddd/dvt/data.html.
2. Mohamad Alkhouli MD M, Craig R, Narins MD, Farhan Raza MD, Riyaz Bashir MBBS. Inferior Vena Cava Thrombosis. Journal of American College of Cardiology: Cardiovascular Interventions. 2016;9(7):629-43.
3. T. Raymond Foley M, FACC; Stephen W. Waldo, MD, FACC; Ehrin J. Armstrong, MD, FACC. Iliofemoral Deep Vein Thrombosis www.acc.org: American College of Cardiology; 2015 [Available from: https://www.acc.org/latest-in-cardiology/articles/2015/11/23/13/39/iliofemoral-deep-vein-thrombosis.
4. Drew Fleck HA, Fadi Shamoun, Grace Knuttilen, Sailendra Naidu, and Rahmi Oklu. Catheter-directed thrombolysis of deep vein thrombosis: literature review and practice considerations. Cardiovascular Diagnosis and Therapy. 2017;7.
5. Suresh Vedantham MD, Samuel Z. Goldhaber, M.D., Jim A. Julian, M.Math., Susan R. Kahn, M.D., et al., for the ATTRACT Trial Investigators. Pharmacomechanical Catheter-Directed Thrombolysis for Deep-Vein Thrombosis. New England Journal of Medicine 2017.
6. Watson L BC, Armon MP. Thrombolysis for acute deep vein thrombosis (Review). Cochrane Library. 2016(11).
7. Mohamad Alkhouli MCJZ, MD; Chad J. Zack, MD; Huaqing Zhao, PhD; Irfan Shafi, MD; Riyaz Bashir, MD. Comparative Outcomes of Catheter-Directed Thrombolysis Plus Anticoagulation Versus Anticoagulation Alone in the Treatment of
Inferior Vena Caval Thrombosis. American Heart Association 2015.

8. Suresh Vedantham MD, Akhilesh K. Sista, MD, Seth J. Klein, MD, Lina Nayak, MD, Mahmood K. Razavi M, Sanjeeva P. Kalva, MD, Wael E. Saad, MD, Sean R. Dariushnia, MD., Drew M. Caplin M, Christine P. Chao, MD, Suvranu Ganguli, MD, T. Gregory Walker, MD, and, Boris Nikolic M, MBA. Quality Improvement Guidelines for the Treatment of Lower-Extremity Deep Vein Thrombosis with Use of Endovascular Thrombus Removal. Journal of Vascular Interventional Radiology. 2014;25.

9. Archie M AM, O’Connell J, DeRubertis BG. Underutilization of Thrombolytic Therapy for Patients Diagnosed with Acute Deep Venous Thrombosis in the Outpatient Setting. Annals of Vascular Surgery. 2018.

10. PC Wong YC, Y Law, Stephen WK Cheng. Percutaneous mechanical thrombectomy in the treatment of acute iliofemoral deep vein thrombosis: a systematic review. Hong Kong Medical Journal. 2019;25.